Insight

Pashtoon Kasi: With BOT/BAL in our NEST trial, we are seeing ctDNA decline and CLEAR within days to 2-4 weeks

Photo from Pashtoon Kasi/LinkedIn

Mar 26, 2024, 15:02

Pashtoon Kasi: With BOT/BAL in our NEST trial, we are seeing ctDNA decline and CLEAR within days to 2-4 weeks

Pashtoon Kasi, Director for Colorectal Cancer Research at Weill Cornell Medicine shared on LinkedIn:

“We grossly underestimate how quickly immunotherapy can work. Especially with BOT/BAL (botensilimab) in our NEST trial, we are seeing ctDNA decline and CLEAR within days to 2-4 weeks. Unprecedented!

March is Colorectal Cancer Awareness Month.”

No alternative text description for this image

Proceed to the article.
Source: Pashtoon Kasi/LinkedIn

BOT/BAL botensilimab cancer colorectal cancer Colorectal Cancer Awareness Month immunotherapy for colorectal cancer NEST trial OncoDaily Oncology Pashtoon Kasi Weill Cornell Medicine

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success